Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...

ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma.

A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Pancreatic Cancer.

EEDVD-682 is under clinical development by EnGeneIC and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase ...

SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

OMO-103 is under development for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC), advanced high-grade osteosarcoma and metastatic pancreatic cancer. The therapeutic candidate is a ...